Valneva is a new European Biotech company focused on vaccines and antibodies.
It was created in 2013 by a merger between Intercell AG and Vivalis SA, combining the two value propositions – antibody discovery and vaccines development.
Valneva’s mission is to use the power of innovation to excel in both focus areas, trough collaboration with industrial partners. It generates revenue from diverse sources from both its marketed product and new commercial partnerships.
It has a portfolio of product candidates (in-house as well as partnered) and technology platforms that are becoming widely adopted by the biopharmaceutical industry at large.
The internationally experienced management team has a proven track-record across research, development, manufacturing and commercialization.